#PP **********************************************************6444479999************************* #PP **********************************************************966666************************* #PP **********************************************************966666************************* a) Bc5 RNA was omitted (see Supplementary Figure S1 ) in GenBank record (GenBank accession: NC_017208.1).
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Section C: Primers information and plasmids construction procedure. Bc5'_F CATGCCATGGTCTCAAAAAGAAAAAATAAATGGG
5' UTR_R CGGGATCCACTTCTTATGAACCGAATATTTCGAAC
Bc4'_F CATGCCATGGTCTCAAAAAGAAAAAATAAATGGG
The restriction sites are underlined as bold Italic. (Table 1) , and transformants were verified by sequencing. Plasmids were constructed as follows:
Different strains containing single plasmids or double plasmids were transformed or co-transformed into corresponding E. coli strains
Construction of plasmids for β-galactosidase assay in E. coli Trans5α with various c-di-GMP riboswitch encoding regions in promotors
Gene lacZ was cut (fragments between Hind III and Kpn I) from our previously engineered plasmid pHT1K-lacZ(UTR) 3 and BamH I) into pRP1028-lacZ to generate plasmids pRP1028-Bc5'-lacZ, pRP1028-Bc4-5'-lacZ and pRP1028-Bc3-5'-lacZ, respectively (Supplementary Figure S6) .
Construction of plasmids for PleD expression in E. coli
A previous reported DGC PleD 5 was used for the synthesis of intracellular c-di-GMP. Amplification of its encoding gene pleD (primer pair: pleD_F and pleD_R) was carried out using a gift PleD expression plasmid 6 as a template, and then fused (between Xba I and Sal I) into pET-28b(+) (Novagen, catalog S11 number: 69865-3) to form pET-28b(+)-pleD (Supplementary Figure S7) . Subsequently, a fragment carrying Ptac promoter was amplified (primer pair: Ptac_F and Ptac_R) from commercial plasmid pGEX-6P-1 (GE Healthcare Inc., code number: 28-9546-48) to replace the T7 promoter (between Bgl II and Xba I) of pET-28b(+)-pleD, thus the PleD constitutive expression plasmid pET-Ptac-pleD (Supplementary Figure S7) was generated. Plasmid pET-28b(+) was used as a negative control. For construction of pRP0122-Pbe-amcyan_Bc3-5_turborfp, a backbone plasmid pRP0122
Construction of riboswitch
(Supplementary Figure S8) was firstly generated. In fact, pRP0122 was the truncated derivative of pRP1028, in which turborfp gene and Pbe were deleted. To obtain pRP0122, pRP1028 was cleaved with
Pvu II and EcoR I to generate a linearized pRP1028, where the DNA region containing turborfp gene, spectinomycin resistance gene and Pbe was removed. Then, the spectinomycin resistance gene was amplified from pRP1028 using primers speR_F and speR_R (Supplementary Table S6 ) and ligated to the The constructed plasmids were transformed to BL21(DE3) for Congo red assays and expressed proteins of putative DGCs and their variants were subsequently purified (Table 1) . They are co-transformed to BL21(DE3) with pRP0122-Pbe-amcyan_Bc3-5_turborfp to construct the strains for putative DGCs verification (Table 1 ). kanamycin resistance gene; pBR322: pBR322 replicon; lacI: lactose repressor gene.
